

Clinical trials of edoxaban low dose

TrialResults-center www.trialresultscenter.org

1 atrial fibrillation

Trial	Treatments	Patients	Trials design and methods
edoxaban low dose vs warfarin standard dose			
ENGAGE-AF TIMI 48 Low dose , 2013 [NCT00781391] n=7034/7036 follow-up: 2.8 years	edoxaban xxx once daily versus warfarin (INR 2-3)	AF patients (CHADS2 ≥ 2)	double blind 46 countries

More details and results :

- antithrombotics for atrial fibrillation in primary prevention of thromboembolic events at <http://www.trialresultscenter.org/go-Q57>
- direct factor Xa inhibitors for atrial fibrillation in all type of patients at <http://www.trialresultscenter.org/go-Q373>
- direct oral anticoagulant (DAO) for atrial fibrillation in all type of patients at <http://www.trialresultscenter.org/go-Q391>

References

ENGAGE-AF TIMI 48 Low dose, 2013:

Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, pinar J, Ruzylo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013 Nov 28;369:2093-104 [[24251359](#)]

Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010;160:635-41 [[20934556](#)] [10.1016/j.ahj.2010.06.042](https://doi.org/10.1016/j.ahj.2010.06.042)